<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>endocrinology</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>endocrinology | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="A set of circulating microRNAs belonging to the 14q32 chromosomic locus identifies two clinically and phenotypically different subgroups of individuals with recent onset Stage 3 type 1 diabetes
Authors: Sebastiani, G.; Grieco, G. E.; Bruttini, M.; Auddino, S.; Mori, A.; Toniolli, M.; Fignani, D.; Licata, G.; Nigi, L.; Formichi, C.; Pugliese, A.; Evans-Molina, C.; Overbergh, L.; Tree, T.; Peakman, M.; Mathieu, C.; Dotta, F.; INNODIA, Score: 6.4, Published: 2023-10-09 DOI: 10.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/endocrinology/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="endocrinology" />
<meta property="og:description" content="A set of circulating microRNAs belonging to the 14q32 chromosomic locus identifies two clinically and phenotypically different subgroups of individuals with recent onset Stage 3 type 1 diabetes
Authors: Sebastiani, G.; Grieco, G. E.; Bruttini, M.; Auddino, S.; Mori, A.; Toniolli, M.; Fignani, D.; Licata, G.; Nigi, L.; Formichi, C.; Pugliese, A.; Evans-Molina, C.; Overbergh, L.; Tree, T.; Peakman, M.; Mathieu, C.; Dotta, F.; INNODIA, Score: 6.4, Published: 2023-10-09 DOI: 10." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/endocrinology/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2023-10-15T10:38:01+00:00" />
<meta property="article:modified_time" content="2023-10-15T10:38:01+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="endocrinology"/>
<meta name="twitter:description" content="A set of circulating microRNAs belonging to the 14q32 chromosomic locus identifies two clinically and phenotypically different subgroups of individuals with recent onset Stage 3 type 1 diabetes
Authors: Sebastiani, G.; Grieco, G. E.; Bruttini, M.; Auddino, S.; Mori, A.; Toniolli, M.; Fignani, D.; Licata, G.; Nigi, L.; Formichi, C.; Pugliese, A.; Evans-Molina, C.; Overbergh, L.; Tree, T.; Peakman, M.; Mathieu, C.; Dotta, F.; INNODIA, Score: 6.4, Published: 2023-10-09 DOI: 10."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "endocrinology",
      "item": "https://trxiv.yorks0n.com/posts/endocrinology/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "endocrinology",
  "name": "endocrinology",
  "description": "A set of circulating microRNAs belonging to the 14q32 chromosomic locus identifies two clinically and phenotypically different subgroups of individuals with recent onset Stage 3 type 1 diabetes\nAuthors: Sebastiani, G.; Grieco, G. E.; Bruttini, M.; Auddino, S.; Mori, A.; Toniolli, M.; Fignani, D.; Licata, G.; Nigi, L.; Formichi, C.; Pugliese, A.; Evans-Molina, C.; Overbergh, L.; Tree, T.; Peakman, M.; Mathieu, C.; Dotta, F.; INNODIA, Score: 6.4, Published: 2023-10-09 DOI: 10.",
  "keywords": [
    
  ],
  "articleBody": " A set of circulating microRNAs belonging to the 14q32 chromosomic locus identifies two clinically and phenotypically different subgroups of individuals with recent onset Stage 3 type 1 diabetes\nAuthors: Sebastiani, G.; Grieco, G. E.; Bruttini, M.; Auddino, S.; Mori, A.; Toniolli, M.; Fignani, D.; Licata, G.; Nigi, L.; Formichi, C.; Pugliese, A.; Evans-Molina, C.; Overbergh, L.; Tree, T.; Peakman, M.; Mathieu, C.; Dotta, F.; INNODIA, Score: 6.4, Published: 2023-10-09 DOI: 10.1101/2023.10.08.23296650\nPrevious research has indicated that circulating microRNAs are linked to the onset and progression of type 1 diabetes mellitus (T1DM), making them potential biomarkers for the disease. In this study, we employed a multiplatform sequencing approach to analyze circulating microRNAs in an extended cohort of individuals recently diagnosed with T1DM from the European INNODIA consortium. Our findings revealed that a specific set of microRNAs located within the T1DM susceptibility chromosomal locus 14q32 distinguishes two distinct subgroups of T1DM individuals. To validate our results, we conducted additional analyses on a second cohort of T1DM individuals, independently confirming the identification of these two subgroups, which we have named Cluster A and Cluster B. Remarkably, Cluster B T1DM individuals, who exhibited increased expression of 14q32 miRNAs, displayed a different peripheral blood immunomics profile, possessed a lower T1DM risk HLA genotype, and showed better glycaemic control during follow-up visits compared to Cluster A individuals. Taken together, our findings suggest that this specific set of circulating microRNAs located in the 14q32 locus can effectively identify T1DM subgroups with distinct characteristics and different clinical outcomes during follow-up. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=161 SRC=\"FIGDIR/small/23296650v1_ufig1.gif\" ALT=\"Figure 1\"\u003e View larger version (33K): org.highwire.dtl.DTLVardef@286b8borg.highwire.dtl.DTLVardef@1acb154org.highwire.dtl.DTLVardef@ae3d20org.highwire.dtl.DTLVardef@12f283b_HPS_FORMAT_FIGEXP M_FIG C_FIG HIGHLIGHTSO_LICirculating miRNA profiles in individuals with newly diagnosed Type 1 Diabetes Mellitus (T1DM) can distinguish two subgroups: Cluster A and Cluster B. C_LIO_LImiR-409-3p, miR-127-3p, and miR-382-5p are increased in the plasma of individuals in Cluster B. C_LIO_LIIndividuals in Cluster B showed lower IAA titers, a reduced prevalence of HLA risk genotype, and an improved glycaemic profile during the follow-up period. C_LIO_LIImmunomic profiling revealed a reduced frequency of pro-inflammatory immune cells and a higher frequency of exhausted T lymphocytes among individuals in Cluster B. C_LI\nSystematic Review of Treatment of Beta-Cell Monogenic Diabetes\nAuthors: Naylor, R. N.; Patel, K. A.; Kettunen, J. L. T.; Männistö, J. M. E.; Stoy, J.; Beltrand, J.; Polak, M.; ADA/EASD PMDI, ; Vilsobll, T.; Greeley, S. A. W.; Hattersley, A. T.; Tuomi, T.\nScore: 6.0, Published: 2023-09-22 DOI: 10.1101/2023.05.12.23289807\nBackgroundBeta-cell monogenic forms of diabetes are the area of diabetes care with the strongest support for precision medicine. We reviewed treatment of hyperglycemia in GCK-related hyperglycemia, HNF1A- HNF4A- and HNF1B-diabetes, Mitochondrial diabetes (MD) due to m.3243A\u003eG variant, 6q24-transient neonatal diabetes (TND) and SLC19A2-diabetes. MethodsSystematic reviews with data from PubMed, MEDLINE and Embase were performed for the different subtypes. Individual and group level data was extracted for glycemic outcomes in individuals with genetically confirmed monogenic diabetes. Results147 studies met inclusion criteria with only six experimental studies and the rest being single case reports or cohort studies. Most studies had moderate or serious risk of bias. For GCK-related hyperglycemia, six studies (N=35) showed no deterioration in HbA1c on discontinuing glucose lowering therapy. A randomized trial (n=18 per group) showed that sulfonylureas (SU) were more effective in HNF1A-diabetes than in type 2 diabetes, and cohort and case studies supported SU effectiveness in lowering HbA1c. Two crossover trials (n=15 and n=16) suggested glinides and GLP-1 receptor agonists might be used in place of SU. Evidence for HNF4A-diabetes was limited. While some patients with HNF1B-diabetes (n=301) and MD (n=250) were treated with oral agents, most were on insulin. There was some support for the use of oral agents after relapse in 6q24-TND, and for thiamine improving glycemic control and reducing insulin requirement in SLC19A2-diabetes (less than half achieved insulin-independency). ConclusionThere is limited evidence to guide the treatment in monogenic diabetes with most studies being non-randomized and small. The data supports: no treatment in GCK-related hyperglycemia; SU for HNF1A-diabetes. Further evidence is needed to examine the optimum treatment in monogenic subtypes.\n",
  "wordCount" : "666",
  "inLanguage": "en",
  "datePublished": "2023-10-15T10:38:01Z",
  "dateModified": "2023-10-15T10:38:01Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/endocrinology/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      endocrinology
    </h1>
    <div class="post-meta"><span>updated on October 15, 2023</span>

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.10.08.23296650">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.10.08.23296650" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.10.08.23296650">
        <p class="paperTitle">A set of circulating microRNAs belonging to the 14q32 chromosomic locus identifies two clinically and phenotypically different subgroups of individuals with recent onset Stage 3 type 1 diabetes</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.10.08.23296650" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.10.08.23296650" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Sebastiani, G.; Grieco, G. E.; Bruttini, M.; Auddino, S.; Mori, A.; Toniolli, M.; Fignani, D.; Licata, G.; Nigi, L.; Formichi, C.; Pugliese, A.; Evans-Molina, C.; Overbergh, L.; Tree, T.; Peakman, M.; Mathieu, C.; Dotta, F.; INNODIA,  </p>
        <p class="info">Score: 6.4, Published: 2023-10-09 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.10.08.23296650' target='https://doi.org/10.1101/2023.10.08.23296650'> 10.1101/2023.10.08.23296650</a></p>
        <p class="abstract">Previous research has indicated that circulating microRNAs are linked to the onset and progression of type 1 diabetes mellitus (T1DM), making them potential biomarkers for the disease. In this study, we employed a multiplatform sequencing approach to analyze circulating microRNAs in an extended cohort of individuals recently diagnosed with T1DM from the European INNODIA consortium. Our findings revealed that a specific set of microRNAs located within the T1DM susceptibility chromosomal locus 14q32 distinguishes two distinct subgroups of T1DM individuals. To validate our results, we conducted additional analyses on a second cohort of T1DM individuals, independently confirming the identification of these two subgroups, which we have named Cluster A and Cluster B. Remarkably, Cluster B T1DM individuals, who exhibited increased expression of 14q32 miRNAs, displayed a different peripheral blood immunomics profile, possessed a lower T1DM risk HLA genotype, and showed better glycaemic control during follow-up visits compared to Cluster A individuals. Taken together, our findings suggest that this specific set of circulating microRNAs located in the 14q32 locus can effectively identify T1DM subgroups with distinct characteristics and different clinical outcomes during follow-up.

GRAPHICAL ABSTRACT

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=161 SRC=&#34;FIGDIR/small/23296650v1_ufig1.gif&#34; ALT=&#34;Figure 1&#34;&gt;
View larger version (33K):
org.highwire.dtl.DTLVardef@286b8borg.highwire.dtl.DTLVardef@1acb154org.highwire.dtl.DTLVardef@ae3d20org.highwire.dtl.DTLVardef@12f283b_HPS_FORMAT_FIGEXP  M_FIG C_FIG HIGHLIGHTSO_LICirculating miRNA profiles in individuals with newly diagnosed Type 1 Diabetes Mellitus (T1DM) can distinguish two subgroups: Cluster A and Cluster B.
C_LIO_LImiR-409-3p, miR-127-3p, and miR-382-5p are increased in the plasma of individuals in Cluster B.
C_LIO_LIIndividuals in Cluster B showed lower IAA titers, a reduced prevalence of HLA risk genotype, and an improved glycaemic profile during the follow-up period.
C_LIO_LIImmunomic profiling revealed a reduced frequency of pro-inflammatory immune cells and a higher frequency of exhausted T lymphocytes among individuals in Cluster B.
C_LI</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.05.12.23289807">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.05.12.23289807" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.05.12.23289807">
        <p class="paperTitle">Systematic Review of Treatment of Beta-Cell Monogenic Diabetes</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.05.12.23289807" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.05.12.23289807" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Naylor, R. N.; Patel, K. A.; Kettunen, J. L. T.; Männistö, J. M. E.; Stoy, J.; Beltrand, J.; Polak, M.; ADA/EASD PMDI,  ; Vilsobll, T.; Greeley, S. A. W.; Hattersley, A. T.; Tuomi, T.</p>
        <p class="info">Score: 6.0, Published: 2023-09-22 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.05.12.23289807' target='https://doi.org/10.1101/2023.05.12.23289807'> 10.1101/2023.05.12.23289807</a></p>
        <p class="abstract">BackgroundBeta-cell monogenic forms of diabetes are the area of diabetes care with the strongest support for precision medicine. We reviewed treatment of hyperglycemia in GCK-related hyperglycemia, HNF1A- HNF4A- and HNF1B-diabetes, Mitochondrial diabetes (MD) due to m.3243A&gt;G variant, 6q24-transient neonatal diabetes (TND) and SLC19A2-diabetes.

MethodsSystematic reviews with data from PubMed, MEDLINE and Embase were performed for the different subtypes. Individual and group level data was extracted for glycemic outcomes in individuals with genetically confirmed monogenic diabetes.

Results147 studies met inclusion criteria with only six experimental studies and the rest being single case reports or cohort studies. Most studies had moderate or serious risk of bias.

For GCK-related hyperglycemia, six studies (N=35) showed no deterioration in HbA1c on discontinuing glucose lowering therapy. A randomized trial (n=18 per group) showed that sulfonylureas (SU) were more effective in HNF1A-diabetes than in type 2 diabetes, and cohort and case studies supported SU effectiveness in lowering HbA1c. Two crossover trials (n=15 and n=16) suggested glinides and GLP-1 receptor agonists might be used in place of SU. Evidence for HNF4A-diabetes was limited. While some patients with HNF1B-diabetes (n=301) and MD (n=250) were treated with oral agents, most were on insulin. There was some support for the use of oral agents after relapse in 6q24-TND, and for thiamine improving glycemic control and reducing insulin requirement in SLC19A2-diabetes (less than half achieved insulin-independency).

ConclusionThere is limited evidence to guide the treatment in monogenic diabetes with most studies being non-randomized and small. The data supports: no treatment in GCK-related hyperglycemia; SU for HNF1A-diabetes. Further evidence is needed to examine the optimum treatment in monogenic subtypes.</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2023 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        · Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
